Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort.
Alex HandyAmitava BanerjeeAngela M WoodCaroline DaleCathie L M SudlowChristopher TomlinsonDaniel M BeanJohan H ThygesenMehrdad A MizaniMichail KatsoulisRohan TakharSam HollingsSpiros DenaxasVenexia WalkerRichard James Butler DobsonReecha Sofatnull nullPublished in: Heart (British Cardiac Society) (2022)
Pre-existing AT use may be associated with lower odds of COVID-19 death and, while not evidence of causality, provides further incentive to improve AT coverage for eligible individuals with AF.
Keyphrases
- atrial fibrillation
- coronavirus disease
- sars cov
- oral anticoagulants
- left atrial
- left atrial appendage
- catheter ablation
- direct oral anticoagulants
- heart failure
- respiratory syndrome coronavirus
- percutaneous coronary intervention
- healthcare
- emergency department
- adipose tissue
- coronary artery disease
- electronic health record
- glycemic control
- insulin resistance